OSA-Direct
Friday, 17 Nov 2017

Thin Film Electronics and Ypsomed partner to make medical devices "smart"

Ypsomed and Thinfilm are working together on the plans for the realisation of YpsoMate Smart as a further platform product of Ypsomed

28 Oct 2015 | Editor

The Ypsomed Group has announced in its semi-annual report that the company will collaborate with Thin Film Electronics (Thinfilm) to incorporate the company's NFC OpenSense technology into its line of YpsoMate autoinjection devices.

No further details where mention in the original press release but further details can be found in the semi-annual report. An extract from the report is provided below.

Extract from the semi-annual report

Pioneering cooperation with Thinfilm The next important step in this rapidly developing field has already been made. Ypsomed has recently established a cooperation with the Norwegian company Thinfilm. Thinfilm is a market leader in the area of "printed electronics", electronic circuits that can be produced extremely cost effectively using standard printing techniques. Ypsomed and Thinfilm are working together on the plans for the realisation of "YpsoMate® Smart" as a further platform product of Ypsomed. YpsoMate® Smart is being developed from the successful autoinjector YpsoMate®, thanks to the addition of an extra, cost-effective "smart label", which can wirelessly transfer data based on itsstatus to smartphones using NFC (Near Field Communication).

This enables pharmaceutical partners to realise numerous exciting applications. For example, by scanning with the smartphone, it is possible to call up corresponding multimedia operating instructions before using the autoinjector. And once the medicine has been administered the patient can send the conclusive confirmation that the injection has been successfully administered. But it is not just for autoinjectors but also for the UnoPen™ injection pen that Ypsomed has developed concepts of how these can be turned into "smart devices" through innovative, cost-effective technological solutions.

The challenge here is that the UnoPen™ – in line with current market trends – is a disposable device that is thrown away after the period of use of a few days or weeks. The current concept envisages a reusable addition to the pen to begin with, however with the final result being such a radical cost optimisation that the smart components can be incorporated individually into each UnoPen™.

Source: Ypsomed Group

www.thinfilm.no    www.ypsomed.com   


About Thin Film Electronics

Thinfilm is a leader in the development of Printed Electronics. The first to commercialize printed, rewritable memory, the Company is creating printed systems that include memory, sensing, display, and wireless communication, all at a low cost unmatched by any other electronic technology. Thinfilm's roadmap integrates technology from a strong and growing ecosystem of partners to enable the Internet of Everything by bringing intelligence to disposable goods.

Thin Film Electronics ASA ("Thinfilm") is a publicly listed Norwegian company with headquarters in Oslo, Norway; product development and production in Linköping, Sweden; product development, production, and business development in San Jose, California, USA; and sales offices in the United States, Japan, and Singapore.

Source: Thin Film Electronics

About Ypsomed Group

The Ypsomed Group is the leading developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with 30 years of experience.

Founded in 2003 from the well-known company Disetronic Medical Systems, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility, autoimmune diseases, oncology and other therapeutic areas.

Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading respectively. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems.

With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements, and contract development and manufacturing, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf in Switzerland and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,100 employees.

Source: Ypsomed Group


login

cintelliq logo